SAMHSA & Federal Substance Abuse and Mental Health Programs

The Substance Abuse and Mental Health Services Administration (SAMHSA) is the federal agency within HHS responsible for behavioral health policy — overseeing the primary federal funding streams for substance use disorder treatment and mental health services, running the 988 Suicide and Crisis Lifeline, and tracking national data through the annual National Survey on Drug Use and Health. With an annual budget of approximately $7.4 billion (FY2026 enacted under the Further Consolidated Appropriations Act, 2026, P.L. 119-75), SAMHSA funds two major block grants to states: the Substance Use Prevention, Treatment & Recovery Services Block Grant (SUPTRS, formerly SABG) (~$2.008 billion/year FY2025; $2.028 billion FY2026 enacted) and the Community Mental Health Services Block Grant (MHBG) ($1.008 billion/year, sustained in FY2026). The opioid overdose crisis defines the policy context: approximately 70,000–80,000 Americans die from drug overdoses annually, primarily from illicit fentanyl, driving massive federal investment in harm reduction, naloxone distribution, medication-assisted treatment (buprenorphine/methadone), and crisis intervention. The 988 Suicide and Crisis Lifeline — launched in July 2022 — now handles over 5 million contacts per year and represents the largest new federal behavioral health infrastructure since deinstitutionalization. SAMHSA's programs operate through a fragmented delivery system of state agencies, community mental health centers, federally qualified health centers, and private providers — with access and quality varying dramatically by geography, state funding decisions, and workforce capacity.

Current Law (2026)

Legal Authority

• 42 U.S.C. § 290aa — SAMHSA establishment (Administrator appointed by President; agency within HHS responsible for reducing the impact of substance abuse and mental illness on America's communities)
• 42 U.S.C. § 290bb — Substance Abuse Prevention and Treatment Block Grant (formula grants to states; states must use funds for prevention, treatment, and recovery support services; maintenance of effort requirement; set-aside for primary prevention: 20%)
• 42 U.S.C. § 290bb-25 — Community Mental Health Services Block Grant (formula grants to states for community-based mental health services; states must submit plans identifying needs and describe how funds will be used)
• 42 U.S.C. § 290bb-36 — 988 Suicide & Crisis Lifeline (national suicide prevention and mental health crisis line; network of local and regional crisis centers; Veterans Crisis Line)
• 42 U.S.C. § 290dd-2 — Confidentiality of substance use disorder patient records (42 CFR Part 2 — federal privacy protections for substance use disorder treatment records; stricter than HIPAA; consent required for disclosure)
• 42 U.S.C. § 290cc — Projects for Assistance in Transition from Homelessness (PATH) (grants to states for outreach, treatment, and support services for people with serious mental illness who are homeless or at risk)

How It Works

SAMHSA is the federal agency leading efforts to reduce the impact of substance abuse and mental illness on American communities. With a budget of approximately $7.4 billion (FY2026 enacted), SAMHSA funds prevention, treatment, and recovery services primarily through block grants to states and targeted grant programs. Two major block grants distribute approximately $3.0 billion annually: the Substance Use Prevention, Treatment & Recovery Services Block Grant (SUPTRS, formerly SABG) (~$2.0 billion FY2025; $2.028 billion FY2026, requiring a 20% set-aside for prevention and prioritizing injection drug users, pregnant and postpartum women, and people with co-occurring disorders) and the Community Mental Health Services Block Grant (MHBG) ($1.008 billion, focused on adults with serious mental illness and children with serious emotional disturbances). Beyond block grants, the State Opioid Response (SOR) grant program provides approximately $1.6 billion annually (FY2026 enacted) for prevention, treatment — including medication-assisted treatment (MAT) with buprenorphine, methadone, and naltrexone — and recovery services; SAMHSA also certifies Opioid Treatment Programs (OTPs), the regulatory framework governing methadone clinics. The SUPPORT Act (2018) expanded access by allowing nurse practitioners and physician assistants to prescribe buprenorphine without a special waiver.

The 988 Suicide & Crisis Lifeline, launched July 2022, provides free, confidential crisis support via phone call, text, or chat — 24/7, nationwide — routing contacts to approximately 200 local and regional crisis centers, with a dedicated Veterans Crisis Line (press 1). 988 is designed to transform crisis response from law enforcement and emergency rooms to specialized behavioral health intervention. Mental health parity is enforced by DOL, CMS, and Treasury under the MHPAEA, but SAMHSA provides technical assistance ensuring that insurance coverage for mental health and SUD is no more restrictive than coverage for medical/surgical conditions. 42 CFR Part 2 provides special confidentiality protections for substance use disorder treatment records — protections stricter than HIPAA — prohibiting disclosure without patient consent even for treatment coordination, with limited exceptions; recent CARES Act reforms have moved toward aligning Part 2 with HIPAA's treatment, payment, and operations consent framework while maintaining core privacy protections.

How It Affects You

If you or someone you know is in mental health crisis or considering suicide: Call or text 988 — the Suicide & Crisis Lifeline launched July 2022 — for immediate, free, confidential support, 24 hours a day, 7 days a week. You can call (voice), text (text "988"), or chat at 988lifeline.org. You'll be connected to a trained counselor at a local crisis center. Veterans, service members, and their families: dial 988 and press 1 to reach the Veterans Crisis Line, which has specialized military-experienced counselors. If you're in immediate danger, 911 is still appropriate — but for mental health crises, 988 is specifically designed to connect you to behavioral health response rather than police response, in many communities now pairing mobile crisis teams with the line. The 988 system handles approximately 5+ million contacts per year. If you're calling on behalf of someone else (a family member you're worried about), 988 counselors can help you figure out what to do and how to help, not just the person in crisis.

If you're looking for substance use disorder treatment for yourself or a family member: findtreatment.gov (SAMHSA's treatment locator) is the starting point — searchable by location, type of treatment, payment accepted (including Medicaid, sliding scale, free), and services offered (detox, MAT, residential, outpatient). For opioid use disorder specifically, medication-assisted treatment (MAT) — buprenorphine/Suboxone, methadone (through licensed OTPs), and naltrexone/Vivitrol — is the evidence-based gold standard and is now more accessible than ever. The SUPPORT Act (2018) and subsequent rule changes eliminated the DATA waiver requirement for buprenorphine prescribers — any licensed physician, nurse practitioner, or PA can now prescribe buprenorphine for OUD without a special waiver. Coverage: under the ACA, substance use disorder treatment is an essential health benefit — all marketplace plans and Medicaid expansion plans must cover it. 42 CFR Part 2 provides special privacy protections for SUD treatment records — your treatment records from a federally assisted SUD program cannot be shared (including for treatment coordination) without your written consent, except in medical emergencies. These records are protected even from your other providers unless you consent.

If you're a family member trying to support a loved one with addiction or mental illness: SAMHSA's resources are designed for family members as much as patients. SAMHSA's National Helpline (1-800-662-4357) is free, confidential, 24/7, and helps both individuals and family members find treatment and support resources in their area — even without insurance. The National Alliance on Mental Illness (NAMI) at nami.org offers free family education programs (Family-to-Family is a 8-session course for family members of adults with serious mental illness) and peer support groups. For families navigating a loved one's addiction, SMART Recovery Family & Friends and Al-Anon/Nar-Anon offer peer support models. The hardest insight in helping a loved one with SUD: you cannot force recovery, but you can affect the conditions around it. SAMHSA's "Talk. They Hear You." campaign (samhsa.gov/talk) provides communication guides for families. If your loved one is at risk of overdose, naloxone (Narcan) is available without a prescription at many pharmacies — carrying it is a potentially life-saving intervention.

If you're a healthcare provider, employer, or benefits administrator dealing with behavioral health coverage: 42 CFR Part 2 is the federal regulation you need to know for SUD record handling — it's stricter than HIPAA and requires patient consent for most disclosures of SUD treatment records, including to other treating providers (outside emergency exceptions). Recent CARES Act reforms (effective 2020) and subsequent rulemaking have moved toward HIPAA alignment while maintaining core protections: SUD records can now be shared for treatment, payment, and healthcare operations after a single general consent (similar to HIPAA's TPO framework) rather than requiring specific disclosure-by-disclosure consents. For employers: the Mental Health Parity and Addiction Equity Act (MHPAEA) requires that mental health and SUD benefits be no more restrictive than medical/surgical benefits — enforcement has increased, and insurers are required to provide comparative analyses of their treatment limitation policies to enrollees who request them. The Employee Assistance Program (EAP) is your frontline resource for employees in crisis — ensure your EAP vendor has 988 awareness and updated crisis response protocols.

State Variations

• Community health centers and telehealth services are expanding behavioral health access in underserved areas
• Block grant funds are distributed by formula and administered by state behavioral health agencies
• State Medicaid programs are the largest payer for behavioral health services (see Healthcare Spending Policy for overall spending breakdown) — expansion states have significantly more SUD/MH coverage
• Some states have enacted their own mental health parity laws that exceed federal requirements
• State crisis response systems vary — some have fully implemented 988 with mobile crisis teams; others rely primarily on traditional emergency services
• State marijuana legalization creates tension with federal substance abuse classification and treatment approaches

Implementing Regulations

• 42 CFR Part 8 — Medications for the Treatment of Opioid Use Disorder: the SAMHSA/CSAT rules governing the certification, accreditation, and treatment standards for Opioid Treatment Programs (OTPs) — the licensed facilities (primarily methadone clinics) that dispense methadone and other approved medications for OUD in a structured clinical setting. Key provisions:

  • § 8.11 — OTP certification requirement: before dispensing Schedule II opioid medications for maintenance or detoxification treatment, a facility must be certified by SAMHSA as an OTP; certification requires state authority approval, DEA registration as a narcotic treatment program, and accreditation by a SAMHSA-approved accreditation body; uncertified facilities dispensing methadone for OUD treatment violate both Part 8 and the Controlled Substances Act; application is on Form SMA-162
  • § 8.12 — Federal OUD treatment standards: OTPs must provide treatment in accordance with these standards as a condition of certification; the standards address: (a) patient admission (intake evaluation, medical history, substance use history, documentation of dependence); (b) medication dispensing (take-home privileges for stable patients — initially no take-homes, then 1-day/week, building to up to 30-day take-home supplies for patients in stable long-term recovery); (c) counseling (at least one counseling session before maintenance begins; ongoing counseling throughout); (d) medical supervision (physician must establish treatment protocol and oversight); (e) drug testing (urinalysis at admission and randomly during treatment to verify compliance); the COVID-19 pandemic resulted in temporary relaxation of take-home restrictions, and SAMHSA's Feb 2, 2024 final rule (89 FR 7528) made the relaxed take-home standards permanent
  • §§ 8.3–8.7 — Accreditation requirement: OTPs must be accredited by a SAMHSA-approved accreditation body (currently: CARF, The Joint Commission, NCQA, and others); accreditation bodies conduct on-site surveys of OTPs against SAMHSA's treatment standards; the accreditation system creates an independent quality oversight layer — SAMHSA will not certify an unaccredited OTP and may revoke the certification of a program that loses accreditation
  • § 8.13 — Secretary's action after loss of accreditation: if an accreditation body revokes an OTP's accreditation, SAMHSA may investigate and conduct its own review; SAMHSA may revoke the OTP's federal certification; this provision maintains SAMHSA's independent authority even after the accreditation body acts
  • § 8.14 — Suspension and revocation of certification: SAMHSA may suspend or revoke certification if the OTP: violates treatment standards, loses DEA registration, loses state authority, engages in fraud or diversion, or otherwise fails to meet certification requirements; suspension is immediate when patient safety is at risk; appeal procedures are in Subpart D (informal review within 30 days of suspension notice)

  Part 8 is the regulatory framework that distinguishes methadone for OUD treatment from illicit opioid use and from other medical uses of methadone (pain management, which is dispensed through regular pharmacies). Methadone for OUD can only be dispensed through certified OTPs — patients must come to the clinic for their dose, at least initially; take-home privileges must be earned through demonstrated stability. This contrasts with buprenorphine (Suboxone), which since the elimination of the DATA waiver requirement in 2023 can be prescribed by any licensed prescriber and dispensed at regular pharmacies. The OTP certification system's geographic bottleneck — there are approximately 1,700 certified OTPs nationwide, concentrated in urban areas — has historically been a major access barrier for rural patients needing methadone. SAMHSA's 2024 final rule (89 FR 7528, Feb 2, 2024) made permanent the COVID-era take-home flexibility and authorized mobile delivery to address the geographic access problem.

• 42 CFR Part 2 — Confidentiality of Substance Use Disorder Patient Records (38 sections — the federal privacy framework for SUD treatment records; stricter than HIPAA, based on 42 U.S.C. § 290dd-2):

  • § 2.12 — Applicability: Part 2 applies to any individual or organization that is federally assisted and holds itself out as providing substance use disorder diagnosis, treatment, or referral for treatment; "federally assisted" is broadly defined — accepting Medicare or Medicaid is sufficient; this means virtually all licensed SUD treatment programs in the U.S. are covered, even those that are primarily privately funded
  • § 2.13 — General confidentiality rule: patient records subject to Part 2 (including any information that would identify a person as having a SUD or receiving SUD treatment) may not be disclosed without the patient's written consent — even to other treating providers — except in specific circumstances; this is the core difference from HIPAA, which permits disclosure for treatment, payment, and healthcare operations without patient consent; the baseline under Part 2 is non-disclosure unless the patient has signed an appropriate consent form
  • § 2.14 — Minor patients: a minor patient who independently seeks SUD treatment has the same confidentiality rights as an adult; parental consent to disclose the minor's records is not required when state law permits minors to seek SUD treatment without parental consent; this provision protects minors seeking help from being exposed to parental discovery
  • § 2.15 — Patients who lack capacity and deceased patients: a patient lacking capacity to consent (due to intoxication, mental illness, incapacity) cannot have records disclosed without a court order or under a specific emergency exception; after a patient's death, records may not be disclosed to survivors or other third parties without a court order
  • § 2.16 — Security and breach notification: Part 2 programs must maintain appropriate physical, technical, and administrative safeguards; breaches of Part 2-protected information require notification to affected patients consistent with applicable HIPAA breach notification rules
  • § 2.17 — Undercover agents and informants: law enforcement may not place an undercover agent or informant in a Part 2 program or obtain records through informants without a court order — a specific prohibition that goes beyond HIPAA and reflects Congress's intent to protect the treatment environment from law enforcement surveillance
  • § 2.22 — Notice to patients: Part 2 programs must provide written notice to patients at the time of treatment describing the confidentiality protections and their limits; the notice must be written in plain language and in the patient's primary language if reasonably possible
  • § 2.23 — Patient access: Part 2 does not restrict patients' own access to their records; patients have the right to obtain copies of their SUD treatment records under standard medical records laws
  • Consent requirements: when a patient does authorize disclosure, the written consent form under § 2.31 must include: the name of the program/entity authorized to disclose; the name of the person/organization receiving the disclosure; the patient's name; the purpose of the disclosure; the amount of information to be disclosed; the patient's signature; date; and a statement that the consent may be revoked at any time; disclosures are limited to the minimum necessary to accomplish the stated purpose
  • Law enforcement exceptions (§§ 2.61–2.67): Part 2 records may be disclosed to law enforcement only through: (1) a court order issued after an in camera proceeding; (2) a crime on program premises exception (limited); or (3) a narrow medical emergency exception; no routine reporting to law enforcement, no grand jury subpoenas without court order, no reports pursuant to mandatory reporting laws unless a crime was committed at the program

  The 2020 CARES Act and subsequent HHS rulemaking (89 FR 12629, effective 2024) significantly revised Part 2 to align it more closely with HIPAA: SUD treatment records may now be shared for treatment, payment, and healthcare operations after a single general consent (the "TPO consent"), rather than requiring a separate consent for each disclosure. The core protections against law enforcement access and disclosure without any consent remain unchanged. These reforms were intended to facilitate care coordination for patients with both SUD and co-occurring conditions (such as mental illness or chronic disease) while maintaining the fundamental protection that treatment-seeking should not expose patients to criminal or civil liability.

• 42 CFR Part 54 — Charitable Choice regulations (substance abuse treatment providers, religious organization protections)

• 45 CFR Part 96 — Block Grants (81 sections — HHS's omnibus regulation governing multiple federal block grant programs that provide fixed annual funding to states for health and social services with minimal categorical restrictions; the block grant model delegates spending discretion to states within broad federal statutory purposes). Key subparts covering the major grant programs:

  • Subpart A — General Provisions (§§ 96.1–96.30): § 96.1 — scope covers: Community Services Block Grant (CSBG), Preventive Health and Health Services, Alcohol and Drug Abuse and Mental Health Services, Maternal and Child Health, Primary Care, and Substance Abuse Prevention and Treatment (SAPT) block grants; § 96.10 — no particular application form is required; states may apply by submitting any document that demonstrates compliance with statutory assurances; § 96.11 — basis of award: HHS allocates block grant funds to each state based on statutory formulas (population, poverty rates, historical program expenditures); § 96.12 — payments may be made in advance or by reimbursement; § 96.30 — audit requirements follow the Single Audit Act (2 CFR Part 200 Subpart F)
  • Subpart H — Primary Care Block Grant (§§ 96.100–96.102): § 96.101 — before a state may discontinue funding a community health center receiving primary care block grant funds, HHS may review the decision and require continued funding for the center during a transition period; § 96.102 — carryover of unobligated funds requires HHS approval of good cause
  • Subpart J — General Provisions Applying to Multiple Block Grants (§§ 96.110–96.135): § 96.110 — applies to CSBG, Preventive Health, Alcohol/Drug/Mental Health, and MCH grants; § 96.130 — maintenance of effort: states may not use block grant funds to supplant state expenditures for the same purposes (a state cannot replace state-funded substance abuse services with federal block grant funds while cutting the state budget); § 96.134 — states must submit annual reports to HHS on how block grant funds were used
  • Subpart K — Substance Abuse Prevention and Treatment (SAPT) Block Grant (§§ 96.120–96.137): the dominant subpart administered by SAMHSA — approximately $2 billion per year to states for substance abuse prevention and treatment:
    • § 96.122 — application content: states submit annual plans describing how they will use SAPT funds for prevention and treatment programs
    • § 96.123 — required assurances: states must assure that SAPT funds will be expended in accordance with required percentage allocations (§ 96.124) — a minimum percentage to treatment, a minimum to primary prevention
    • § 96.124 — required allocations: states must spend at least 20% of their SAPT grant on primary prevention programs; the remaining 80% may be used for treatment; states must not reduce spending on alcohol and drug abuse services below prior-year levels
    • § 96.126 — intravenous substance abusers: states must ensure capacity in treatment programs for IV drug users within 14 days of a request for services; if no immediate slot is available, interim services must be provided within 48 hours
    • §§ 96.127–96.128 — tuberculosis and HIV requirements: treatment programs funded under SAPT must screen clients for TB and offer TB services; HIV counseling and testing must be offered or referred; states with high HIV prevalence rates among IV drug users must carry out specific risk-reduction programs

  The SAPT Block Grant is one of SAMHSA's primary funding mechanisms for state behavioral health systems — it allows states to allocate funds across prevention, outpatient treatment, residential treatment, and recovery support services based on local need. The set-asides (minimum percentages for prevention; requirements for IV drug user capacity and TB/HIV services) are federal guardrails built into the block grant structure to ensure minimum standards are maintained even as states exercise broad discretion over how to build their behavioral health continuum.

Pending Legislation (119th Congress)

• S 3402 — Ensuring Excellence in Mental Health Act. Would expand and fund certified community behavioral health clinics across Medicare and Medicaid to boost crisis and integrated care. Status: Introduced.
• HR 2904 (Rep. Watson Coleman, D-NJ) — Pursuing Equity in Mental Health Act. Would boost funding and programs to cut youth mental health disparities through targeted research, culturally tailored outreach, and provider training. Status: Introduced.
• HR 6817 — Home-Based Telemental Health Care Act of 2025. Would provide telemental care grants for rural and farm communities, funding broadband and devices at up to $10 million/year for 2025-2029. Status: Introduced.
• S 414 (Sen. Sullivan, R-AK) — ADS for Mental Health Services Act. Would require major social platforms to report annual data on mental-health public service ads to the FTC. Status: Passed Senate.
• S 1878 (Sen. Fischer, R-NE) — ATTAIN Mental Health Act. Would create an ADA-accessible federal grants dashboard for mental health and substance use disorder programs. Status: Introduced.
• HR 4186 (Rep. Krishnamoorthi, D-IL) — Connecting Students with Mental Health Services Act. Would fund K-12 telehealth grants prioritizing rural and high-poverty schools. Status: Introduced.
• HR 5706 (Rep. Ansari, D-AZ) — Mental Health Emergency Responder Act. Grants to build clinician- and EMS-led crisis response teams as alternatives to police. Status: Introduced.
• HR 5725 (Rep. Watson Coleman, D-NJ) — Mental Health Crisis Response Act of 2025. Would fund grants to route 911 mental-health calls to health responders, $25 million/year 2027-2031. Status: Introduced.
• HR 6994 — Mental Health TALK SAFE Act of 2026. Would expand telehealth prescribing for mental health drugs, set strict standards for telehealth companies, and ease cross-state psychiatry practice. Status: Introduced.
• HR 1141 (Rep. Salinas, D-OR) — Gambling Addiction Recovery, Investment, and Treatment Act. Would create federal formula grants and research funding for gambling addiction funded by wagering-tax receipts. Status: Introduced.

Recent Developments

• 988 Lifeline implementation continues to expand, though many states face funding and capacity challenges to provide comprehensive crisis response
• The opioid crisis has shifted from prescription opioids to illicit fentanyl — requiring new prevention and treatment strategies
• 42 CFR Part 2 reforms have moved toward HIPAA alignment while preserving core SUD privacy protections
• Psychedelic-assisted therapy (psilocybin, MDMA) is advancing through clinical trials, potentially transforming treatment for PTSD, depression, and addiction
• Youth mental health crisis has driven increased federal investment in children's behavioral health services